Literature DB >> 24057268

Linobiflavonoid inhibits human lung adenocarcinoma A549 cells: effect on tubulin protein.

Dongbo Zhao1, Guang Yang, Qingyang Meng, Junxing Liu, Shuang Yang.   

Abstract

The antitumor bioactivities of linobiflavonoid were studied through evaluating its in vitro cytotoxicity against several cell lines (A549, H1975, SMMC-7721, HEP-2 and Vero cells), with the aid of 3-(4,5)-dimethylthiazoly1)-3,5-diphenytetrazolium bromide (MTT) assay. It was found that linobiflavonoid shows more notable inhibiting activity against A549 cells, with IC50 value of 4.67 μM. Furthermore, western blot analysis revealed that linobiflavonoid is able to increase the expression of β-tubulin, whereas not α-tubulin. In virtuale simulations indicated that linobiflavonoid specifically interacts with the binding pocket which is located at the top of β-tubulin, due to the presence of strong hydrophobic effects between the core templates and the hydrophobic surface of the tubulin protein (TB) binding site. The binding energy (E inter ) was calculated to be -140.47 kcal/mol. Results above suggest that linobiflavonoid possesses anti-A549 properties relating to β-tubulin depolymerization inhibition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24057268     DOI: 10.1007/s11033-013-2711-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

Review 1.  Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics.

Authors:  K H Downing
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

Review 2.  Natural products as sources of new drugs over the period 1981-2002.

Authors:  David J Newman; Gordon M Cragg; Kenneth M Snader
Journal:  J Nat Prod       Date:  2003-07       Impact factor: 4.050

3.  Re: Computed tomography screening for lung cancer: review of screening principles and update on current status.

Authors:  Laura Paleari; Pierluigi Granone; Alfredo Cesario; Patrizia Russo
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

4.  Grafting of zwitterion from cellulose membranes via ATRP for improving blood compatibility.

Authors:  Ping-Sheng Liu; Qiang Chen; Xiang Liu; Bo Yuan; Shi-Shan Wu; Jian Shen; Si-Cong Lin
Journal:  Biomacromolecules       Date:  2009-10-12       Impact factor: 6.988

Review 5.  Anticancer therapy with novel tubulin-interacting drugs.

Authors:  M Kavallaris; N M Verrills; B T Hill
Journal:  Drug Resist Updat       Date:  2001-12       Impact factor: 18.500

Review 6.  Molecular mechanism of antitumor activity of taxanes in lung cancer (Review).

Authors:  Jinshun Zhao; Jee Eun Kim; Eddie Reed; Qingdi Q Li
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

Review 7.  Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system.

Authors:  P Russo; A Catassi; A Cesario; D Servent
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

8.  Peptide length, steric effects, and ion solvation govern zwitterion stabilization in barium-chelated di- and tripeptides.

Authors:  Robert C Dunbar; Jeffrey D Steill; Nick C Polfer; Jos Oomens
Journal:  J Phys Chem B       Date:  2009-08-06       Impact factor: 2.991

9.  4- and 5-aroylindoles as novel classes of potent antitubulin agents.

Authors:  Jing-Ping Liou; Chang-Ying Wu; Hsing-Pang Hsieh; Chi-Yen Chang; Chi-Ming Chen; Ching-Chuan Kuo; Jang-Yang Chang
Journal:  J Med Chem       Date:  2007-08-08       Impact factor: 7.446

Review 10.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

View more
  1 in total

1.  Homoisoflavanone-1 isolated from Polygonatum odoratum arrests the cell cycle and induces apoptosis in A549 cells.

Authors:  Deli Ning; Ming Jin; Tao Xv; Jikai Sun; Min Li
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.